Thalidomide: dual benefits in palliative medicine and oncology (Q34375023)

1 August 2017

1 reference

title

Thalidomide: dual benefits in palliative medicine and oncology (English)

1 reference

1 August 2017

0 references

M P Davis

1

1 reference

1 August 2017

E D Dickerson

series ordinal

2

1 reference

1 August 2017

publication date

1 September 2001

1 reference

American Journal of Hospice and Palliative Medicine

1 August 2017

published in

1 reference

1 August 2017

volume

18

1 reference

1 August 2017

issue

5

1 reference

1 August 2017

page(s)

347-351

1 reference

Thalidomide in the treatment of cancer.

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800511

The role of cytokines in cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800511

The effect of an oral nutritional supplement enriched with fish oil on weight-loss in patients with pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800511

Thalidomide in patients with cachexia due to terminal cancer: preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800511

Thalomid (Thalidomide) capsules: a review of the first 18 months of spontaneous postmarketing adverse event surveillance, including off-label prescribing

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800511

New therapies for heart failure: is thalidomide the answer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800511

The use of thalidomide in the management of severe sweating in patients with advanced malignancy: trial report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800511

Intravenous formulations of the enantiomers of thalidomide: pharmacokinetic and initial pharmacodynamic characterization in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800511

Thalidomide in the treatment of the mucocutaneous lesions of the Behçet syndrome. A randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800511

A double-blind study of the sedative effects of the thalidomide enantiomers in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800511

Prevention and management of mucositis in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800511

Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800511

Thalidomide increases both REM and stage 3-4 sleep in human adults: a preliminary study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800511

Decreased toxicity and increased efficacy of cancer chemotherapy using the pineal hormone melatonin in metastatic solid tumour patients with poor clinical status

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800511

Pharmacokinetics and hemodynamic effects of single oral doses of thalidomide in asymptomatic human immunodeficiency virus-infected subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800511

Potential novel uses of thalidomide: focus on palliative care

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800511

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800511

A review of angiogenesis and antiangiogenic therapy with thalidomide in multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800511

Thalidomide as therapy for human immunodeficiency virus-related oral ulcers: a double-blind placebo-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800511

Recent advances in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800511

Effect of a high-fat meal on thalidomide pharmacokinetics and the relative bioavailability of oral formulations in healthy men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800511

Current role of thalidomide in cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800511

Biomedicine. Protein loss in cancer cachexia

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800511

Suppression of tumor growth and metastasis by dietary fish oil combined with vitamins E and C and cisplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800511

Activity of thalidomide in AIDS-related Kaposi's sarcoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800511

Thalidomide for the Treatment of Acquired Immunodeficiency Syndrome–Associated Refractory Oral Ulcers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F104990910101800511

10.1177/104990910101800511

21 January 2018

Identifiers

DOI

1 reference

1 August 2017

1 reference